MHRA authorises Onswik (insulin efsitora alfa) for adults with type 2 diabetes
RegulatoryapprovedOnswikPositive
AI Analysis
Summary
MHRA has authorised Onswik (insulin efsitora alfa), a once-weekly insulin treatment for adults with type 2 diabetes, potentially reducing annual injections from 365 to 52. The regulatory approval represents a significant advance in diabetes treatment options.
Outcome Details
MHRA authorisation for Onswik (insulin efsitora alfa) for adults with type 2 diabetes
Importance:8/10
Sentiment:
0.80
regulatory approvalMHRAinsulin efsitora alfatype 2 diabetesonce-weekly injection
Related Companies
Read the original article
Published by MHRA (UK) on October 13, 2026 1:10 PM